{"id":{"repo_id":"vilnius","oai_identifier":"oai:vu.lt:elaba:308331264"},"canonical_url":"https://search.ndltd.org/etd/vilnius/oai:vu.lt:elaba:308331264","repository":{"repo_id":"vilnius","name":"Vilnius University","base_url":"https://epublications.vu.lt/oai"},"display":{"title":"Resveratrolio poveikis chemoterapinių vaistų sukeltam citotoksiškumui vėžinių ląstelių linijose /","abstract":"The effectiveness of anticancer treatment is often limited by tumor cell heterogeneity, differences in drug sensitivity, and resistance mechanisms. Therefore, combinations of bioactive compounds are investigated as a possible way to enhance anticancer effects or increase cellular sensitivity to chemotherapeutic agents. Resveratrol is a natural polyphenolic compound associated in the literature with effects on cell proliferation, apoptosis, oxidative stress responses, and possible chemosensitization. In addition, resveratrol can interact with lipid membranes, suggesting that membrane-related effects may be relevant when evaluating its mechanisms of action. The aim of this study was to evaluate the effect of resveratrol on the viability of A431 and HCT116 cancer cells, to assess its combinations with etoposide and sorafenib, and to examine resveratrol-induced changes in the electrical properties of model membranes. Cell viability was assessed using the MTT assay, combination effects were additionally evaluated using the Bliss independence model, and membrane-related effects were studied using tBLM systems and electrochemical impedance spectroscopy. The results showed that the effect of resveratrol depended on concentration and cell line. In A431 cells, a clearer tendency toward reduced viability was observed at 50–100 µM resveratrol, whereas in HCT116 cells a significant decrease in viability was detected from 100 µM. Sorafenib caused a clearer concentration-dependent reduction in viability in both cell lines, while the effect of etoposide on HCT116 cells after 24 h was weak. In most cases, combinations of resveratrol with etoposide or sorafenib were not significantly more effective than the corresponding resveratrol-only groups. A significant additional effect was detected only in HCT116 cells treated with 100 µM resveratrol and 1 µM sorafenib; however, Bliss analysis did not confirm a consistent synergistic effect. EIS experiments showed that higher resveratrol concentrations decreased the admittance of model membranes both in membranes with different cholesterol contents and in tBLM systems with different WC14:&#946;ME ratios. Therefore, the initial hypothesis that resveratrol increases ionic permeability of model membranes under the tested conditions was not supported. The data were more consistent with reduced ionic conductance. Overall, this study did not provide convincing evidence that resveratrol consistently enhances the effects of etoposide or sorafenib in A431 and HCT116 cells through increased membrane permeability, but it demonstrates the value of combining biological assays with model membrane studies when evaluating possible membrane-related mechanisms of drug action.","abstract_html":"The effectiveness of anticancer treatment is often limited by tumor cell heterogeneity, differences in drug sensitivity, and resistance mechanisms. Therefore, combinations of bioactive compounds are investigated as a possible way to enhance anticancer effects or increase cellular sensitivity to chemotherapeutic agents. Resveratrol is a natural polyphenolic compound associated in the literature with effects on cell proliferation, apoptosis, oxidative stress responses, and possible chemosensitization. In addition, resveratrol can interact with lipid membranes, suggesting that membrane-related effects may be relevant when evaluating its mechanisms of action. The aim of this study was to evaluate the effect of resveratrol on the viability of A431 and HCT116 cancer cells, to assess its combinations with etoposide and sorafenib, and to examine resveratrol-induced changes in the electrical properties of model membranes. Cell viability was assessed using the MTT assay, combination effects were additionally evaluated using the Bliss independence model, and membrane-related effects were studied using tBLM systems and electrochemical impedance spectroscopy. The results showed that the effect of resveratrol depended on concentration and cell line. In A431 cells, a clearer tendency toward reduced viability was observed at 50–100 µM resveratrol, whereas in HCT116 cells a significant decrease in viability was detected from 100 µM. Sorafenib caused a clearer concentration-dependent reduction in viability in both cell lines, while the effect of etoposide on HCT116 cells after 24 h was weak. In most cases, combinations of resveratrol with etoposide or sorafenib were not significantly more effective than the corresponding resveratrol-only groups. A significant additional effect was detected only in HCT116 cells treated with 100 µM resveratrol and 1 µM sorafenib; however, Bliss analysis did not confirm a consistent synergistic effect. EIS experiments showed that higher resveratrol concentrations decreased the admittance of model membranes both in membranes with different cholesterol contents and in tBLM systems with different WC14:&amp;#946;ME ratios. Therefore, the initial hypothesis that resveratrol increases ionic permeability of model membranes under the tested conditions was not supported. The data were more consistent with reduced ionic conductance. Overall, this study did not provide convincing evidence that resveratrol consistently enhances the effects of etoposide or sorafenib in A431 and HCT116 cells through increased membrane permeability, but it demonstrates the value of combining biological assays with model membrane studies when evaluating possible membrane-related mechanisms of drug action.","abstract_has_math":false,"creators":["Neveras, Vilius,"],"institution":"Institutional Repository of Vilnius University","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-19T10:12:52Z","subjects":[],"languages":["lit"],"rights":["info:eu-repo/semantics/openAccess"],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://repository.vu.lt/VU:ELABAETD308331264&prefLang=en_US","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://repository.vu.lt/VU:ELABAETD308331264&prefLang=en_US","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":"open","embargo_until":null,"access_note":null},"source_record":{"url":"https://epublications.vu.lt/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Avu.lt%3Aelaba%3A308331264","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Neveras, Vilius,"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2026"]},{"key":"dc:publisher","label":"Institution","values":["Institutional Repository of Vilnius University"]},{"key":"dc:relation","label":"Dc Relation","values":["https://epublications.vu.lt/object/elaba:308331264/308331264.pdf"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/bachelorThesis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["lit"]},{"key":"dc:rights","label":"Dc Rights","values":["info:eu-repo/semantics/openAccess"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://repository.vu.lt/VU:ELABAETD308331264&prefLang=en_US"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["The effectiveness of anticancer treatment is often limited by tumor cell heterogeneity, differences in drug sensitivity, and resistance mechanisms. Therefore, combinations of bioactive compounds are investigated as a possible way to enhance anticancer effects or increase cellular sensitivity to chemotherapeutic agents. Resveratrol is a natural polyphenolic compound associated in the literature with effects on cell proliferation, apoptosis, oxidative stress responses, and possible chemosensitization. In addition, resveratrol can interact with lipid membranes, suggesting that membrane-related effects may be relevant when evaluating its mechanisms of action. The aim of this study was to evaluate the effect of resveratrol on the viability of A431 and HCT116 cancer cells, to assess its combinations with etoposide and sorafenib, and to examine resveratrol-induced changes in the electrical properties of model membranes. Cell viability was assessed using the MTT assay, combination effects were additionally evaluated using the Bliss independence model, and membrane-related effects were studied using tBLM systems and electrochemical impedance spectroscopy. The results showed that the effect of resveratrol depended on concentration and cell line. In A431 cells, a clearer tendency toward reduced viability was observed at 50–100 µM resveratrol, whereas in HCT116 cells a significant decrease in viability was detected from 100 µM. Sorafenib caused a clearer concentration-dependent reduction in viability in both cell lines, while the effect of etoposide on HCT116 cells after 24 h was weak. In most cases, combinations of resveratrol with etoposide or sorafenib were not significantly more effective than the corresponding resveratrol-only groups. A significant additional effect was detected only in HCT116 cells treated with 100 µM resveratrol and 1 µM sorafenib; however, Bliss analysis did not confirm a consistent synergistic effect. EIS experiments showed that higher resveratrol concentrations decreased the admittance of model membranes both in membranes with different cholesterol contents and in tBLM systems with different WC14:&#946;ME ratios. Therefore, the initial hypothesis that resveratrol increases ionic permeability of model membranes under the tested conditions was not supported. The data were more consistent with reduced ionic conductance. Overall, this study did not provide convincing evidence that resveratrol consistently enhances the effects of etoposide or sorafenib in A431 and HCT116 cells through increased membrane permeability, but it demonstrates the value of combining biological assays with model membrane studies when evaluating possible membrane-related mechanisms of drug action."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Resveratrolio poveikis chemoterapinių vaistų sukeltam citotoksiškumui vėžinių ląstelių linijose /","Enhancement of chemotherapy-induced cytotoxicity by resveratrol in cancer cell lines."]}]}],"canonical_facts":{"dc:creator":["Neveras, Vilius,"],"dc:date":["2026"],"dc:description":["The effectiveness of anticancer treatment is often limited by tumor cell heterogeneity, differences in drug sensitivity, and resistance mechanisms. Therefore, combinations of bioactive compounds are investigated as a possible way to enhance anticancer effects or increase cellular sensitivity to chemotherapeutic agents. Resveratrol is a natural polyphenolic compound associated in the literature with effects on cell proliferation, apoptosis, oxidative stress responses, and possible chemosensitization. In addition, resveratrol can interact with lipid membranes, suggesting that membrane-related effects may be relevant when evaluating its mechanisms of action. The aim of this study was to evaluate the effect of resveratrol on the viability of A431 and HCT116 cancer cells, to assess its combinations with etoposide and sorafenib, and to examine resveratrol-induced changes in the electrical properties of model membranes. Cell viability was assessed using the MTT assay, combination effects were additionally evaluated using the Bliss independence model, and membrane-related effects were studied using tBLM systems and electrochemical impedance spectroscopy. The results showed that the effect of resveratrol depended on concentration and cell line. In A431 cells, a clearer tendency toward reduced viability was observed at 50–100 µM resveratrol, whereas in HCT116 cells a significant decrease in viability was detected from 100 µM. Sorafenib caused a clearer concentration-dependent reduction in viability in both cell lines, while the effect of etoposide on HCT116 cells after 24 h was weak. In most cases, combinations of resveratrol with etoposide or sorafenib were not significantly more effective than the corresponding resveratrol-only groups. A significant additional effect was detected only in HCT116 cells treated with 100 µM resveratrol and 1 µM sorafenib; however, Bliss analysis did not confirm a consistent synergistic effect. EIS experiments showed that higher resveratrol concentrations decreased the admittance of model membranes both in membranes with different cholesterol contents and in tBLM systems with different WC14:&#946;ME ratios. Therefore, the initial hypothesis that resveratrol increases ionic permeability of model membranes under the tested conditions was not supported. The data were more consistent with reduced ionic conductance. Overall, this study did not provide convincing evidence that resveratrol consistently enhances the effects of etoposide or sorafenib in A431 and HCT116 cells through increased membrane permeability, but it demonstrates the value of combining biological assays with model membrane studies when evaluating possible membrane-related mechanisms of drug action."],"dc:format":["application/pdf"],"dc:identifier":["https://repository.vu.lt/VU:ELABAETD308331264&prefLang=en_US"],"dc:language":["lit"],"dc:publisher":["Institutional Repository of Vilnius University"],"dc:relation":["https://epublications.vu.lt/object/elaba:308331264/308331264.pdf"],"dc:rights":["info:eu-repo/semantics/openAccess"],"dc:title":["Resveratrolio poveikis chemoterapinių vaistų sukeltam citotoksiškumui vėžinių ląstelių linijose /","Enhancement of chemotherapy-induced cytotoxicity by resveratrol in cancer cell lines."],"dc:type":["info:eu-repo/semantics/bachelorThesis"]},"updated_at":"2026-11-19T10:12:52Z"}